Samy Elayi is a Cardiology physician affiliated with University of Kentucky. OpenAlex indexes 35 publications with 837 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1401 Harrodsburg Rd
Lexington, KY 405043751
Telephone
859-276-4429Provider last certified this registry record 8 Apr 2025.
Clinical trials
- The Efficacy of Single Coil Defibrillation Leads for Internal Cardioversion of Atrial Fibrillation
Sponsor: University of Kentucky
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year202510 payments
- Biosense Webster, Inc.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
74.5%Antiarrhythmic24.2%Amiodarone Hcl38%Dofetilide30%Flecainide Acetate19%Multaq9%Propafenone Hcl3%Propafenone Hcl Er2%Part D<11 patientsBeta blocker22.3%Metoprolol Succinate44%Sotalol20%Metoprolol Tartrate17%Carvedilol12%Atenolol4%Bisoprolol Fumarate3%Propranolol Hcl2%Part D<11 patients+ 12 more classes in this area
Blood & clotting
18.5%Factor Xa inhibitor17.9%Eliquis76%Xarelto24%Part D≥102 patientsVitamin K antagonist0.6%Warfarin Sodium100%Part D<11 patientsMetabolism & gastrointestinal
6.5%Potassium supplement4.4%Potassium Chloride82%Klor-Con M2018%Part D<11 patientsProton pump inhibitor1.7%Pantoprazole Sodium54%Omeprazole46%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- REVERSE TAKOTSUBO CARDIOMYOPATHY FOLLOWING CATHETER ABLATION OF ATRIAL FIBRILLATION
Journal of the American College of Cardiology
2020 - Safety of catheter ablation for atrial fibrillation in the octogenarian population
Journal of Cardiovascular Electrophysiology
2019 - Azithromycin-Induced Thrombocytopenia: A Rare Etiology of Drug-Induced Immune Thrombocytopenia
Case Reports in Medicine
2019
Similar KOLs
Other experts from the same institution or the same specialty.
David Moliterno, MD
University of Kentucky
Robert Dipaola
University of Kentucky
Darwin Conwell, MD
University of Kentucky
Phillip Tibbs
University of Kentucky
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”